Produktart
Zustand
Einband
Weitere Eigenschaften
Gratisversand
Land des Verkäufers
Verkäuferbewertung
Verlag: Springer Berlin Heidelberg, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: Buchpark, Trebbin, Deutschland
Buch
Zustand: Sehr gut. Zustand: Sehr gut - Neubindung, Buchschnitt leicht verkürzt, Buchrücken, -ecken, -kanten leicht angestoßen | Seiten: 560 | Sprache: Englisch.
Verlag: Springer, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: booksXpress, Bayonne, NJ, USA
Buch
Soft Cover. Zustand: new.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: booksXpress, Bayonne, NJ, USA
Buch
Hardcover. Zustand: new.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: Lucky's Textbooks, Dallas, TX, USA
Buch
Zustand: New.
Verlag: Springer, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: Lucky's Textbooks, Dallas, TX, USA
Buch
Zustand: New.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: GreatBookPrices, Columbia, MD, USA
Buch
Zustand: New.
Verlag: Springer Berlin Heidelberg, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: moluna, Greven, Deutschland
Buch Print-on-Demand
Gebunden. Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Unique as it gives an overall comprehensive holistic approach and recent developments in combating fungal infectionsSpecial focus is given to the management of pulmonary mycoses in stem cell transplantationIssues of antifungal drug toxicity are discussed.
Verlag: Springer Berlin Heidelberg, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: moluna, Greven, Deutschland
Buch Print-on-Demand
Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Unique as it gives an overall comprehensive holistic approach and recent developments in combating fungal infectionsSpecial focus is given to the management of pulmonary mycoses in stem cell transplantationIssues of antifungal drug toxicity are discussed.
Verlag: Springer, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Buch Print-on-Demand
Zustand: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Buch Print-on-Demand
Zustand: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book.
Verlag: Springer Berlin Heidelberg Aug 2010, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Buch Print-on-Demand
Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Fungi are eukaryotic microorganisms that are closely related to humans at cellular level. Human fungal pathogens belong to various classes of fungi, mainly zygo- cetes, ascomycetes, basidiomycetes, and deuteromycetes. In recent years, fungal infections have dramatically increased as a result of improved diagnosis, high frequency of catheterization, instrumentation, etc. However, the main cause remains the increasing number of immunosuppressed patients, mostly because of HIV infection and indiscriminate usage of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices, and grafts in clinical settings. Presently available means of combating fungal infections are still weak and clumsy compared to control of bacterial infection. The present scenario of antifungal therapy is still based on two classes of antifungal drugs (polyenes and azoles). These drugs are effective in many cases, but display toxicity and limited spectrum of ef cacy. The recent trend towards emergence of drug-resistant isolates in the clinic is an additional problem. In recent years, a few new antifungal drugs have entered the clinics, but they are expected to undergo same fate as the older antifungal drugs. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. However, it is too early to expect any novel drugs, as the antifungal drug discovery program is in the stage of infancy. Interestingly, several novel antifungal drug targets have been identi ed and validated. 560 pp. Englisch.
Verlag: Springer Berlin Heidelberg Dez 2014, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Buch Print-on-Demand
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Fungi are eukaryotic microorganisms that are closely related to humans at cellular level. Human fungal pathogens belong to various classes of fungi, mainly zygo- cetes, ascomycetes, basidiomycetes, and deuteromycetes. In recent years, fungal infections have dramatically increased as a result of improved diagnosis, high frequency of catheterization, instrumentation, etc. However, the main cause remains the increasing number of immunosuppressed patients, mostly because of HIV infection and indiscriminate usage of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices, and grafts in clinical settings. Presently available means of combating fungal infections are still weak and clumsy compared to control of bacterial infection. The present scenario of antifungal therapy is still based on two classes of antifungal drugs (polyenes and azoles). These drugs are effective in many cases, but display toxicity and limited spectrum of ef cacy. The recent trend towards emergence of drug-resistant isolates in the clinic is an additional problem. In recent years, a few new antifungal drugs have entered the clinics, but they are expected to undergo same fate as the older antifungal drugs. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. However, it is too early to expect any novel drugs, as the antifungal drug discovery program is in the stage of infancy. Interestingly, several novel antifungal drug targets have been identi ed and validated. 560 pp. Englisch.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: GreatBookPricesUK, Castle Donington, DERBY, Vereinigtes Königreich
Buch
Zustand: New.
Verlag: Springer Berlin Heidelberg, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Fungi are eukaryotic microorganisms that are closely related to humans at cellular level. Human fungal pathogens belong to various classes of fungi, mainly zygo- cetes, ascomycetes, basidiomycetes, and deuteromycetes. In recent years, fungal infections have dramatically increased as a result of improved diagnosis, high frequency of catheterization, instrumentation, etc. However, the main cause remains the increasing number of immunosuppressed patients, mostly because of HIV infection and indiscriminate usage of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices, and grafts in clinical settings. Presently available means of combating fungal infections are still weak and clumsy compared to control of bacterial infection. The present scenario of antifungal therapy is still based on two classes of antifungal drugs (polyenes and azoles). These drugs are effective in many cases, but display toxicity and limited spectrum of ef cacy. The recent trend towards emergence of drug-resistant isolates in the clinic is an additional problem. In recent years, a few new antifungal drugs have entered the clinics, but they are expected to undergo same fate as the older antifungal drugs. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. However, it is too early to expect any novel drugs, as the antifungal drug discovery program is in the stage of infancy. Interestingly, several novel antifungal drug targets have been identi ed and validated.
Verlag: Springer Berlin Heidelberg, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Fungi are eukaryotic microorganisms that are closely related to humans at cellular level. Human fungal pathogens belong to various classes of fungi, mainly zygo- cetes, ascomycetes, basidiomycetes, and deuteromycetes. In recent years, fungal infections have dramatically increased as a result of improved diagnosis, high frequency of catheterization, instrumentation, etc. However, the main cause remains the increasing number of immunosuppressed patients, mostly because of HIV infection and indiscriminate usage of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices, and grafts in clinical settings. Presently available means of combating fungal infections are still weak and clumsy compared to control of bacterial infection. The present scenario of antifungal therapy is still based on two classes of antifungal drugs (polyenes and azoles). These drugs are effective in many cases, but display toxicity and limited spectrum of ef cacy. The recent trend towards emergence of drug-resistant isolates in the clinic is an additional problem. In recent years, a few new antifungal drugs have entered the clinics, but they are expected to undergo same fate as the older antifungal drugs. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. However, it is too early to expect any novel drugs, as the antifungal drug discovery program is in the stage of infancy. Interestingly, several novel antifungal drug targets have been identi ed and validated.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: GreatBookPrices, Columbia, MD, USA
Buch
Zustand: As New. Unread book in perfect condition.
Verlag: Springer, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: GreatBookPricesUK, Castle Donington, DERBY, Vereinigtes Königreich
Buch
Zustand: As New. Unread book in perfect condition.
Verlag: Springer Verlag, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Buch
Hardcover. Zustand: Brand New. 539 pages. 9.25x6.25x1.25 inches. In Stock.
Verlag: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Buch
Zustand: New. Combating Fungal Infections explores fungal diseases in humans and animals, focusing on the management, fungal pathogens and recent advances in treatment. Issues of antifungal drug toxicity are also discussed, in addition to treatment resistance and diagnostic approaches to fungal infections. Editor(s): Ahmad, Iqbal; Owais, Mohammad; Shahid, Mohammed; Aqil, Farrukh. Num Pages: 559 pages, biography. BIC Classification: MJCM; MMFM; MMG; PSG. Category: (G) General (US: Trade). Dimension: 235 x 155 x 29. Weight in Grams: 848. . 2014. Paperback. . . . .
Verlag: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Buch
Zustand: New. Combating Fungal Infections explores fungal diseases in humans and animals, focusing on the management, fungal pathogens and recent advances in treatment. Issues of antifungal drug toxicity are also discussed, in addition to treatment resistance and diagnostic approaches to fungal infections. Editor(s): Ahmad, Iqbal; Owais, Mohammad; Shahid, Mohammed; Aqil, Farrukh. Num Pages: 539 pages, biography. BIC Classification: MJCM; MMFM; MMG; PSG. Category: (P) Professional & Vocational. Dimension: 243 x 164 x 43. Weight in Grams: 1078. . 2010. 2010th Edition. hardcover. . . . .
Verlag: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG, 2014
ISBN 10: 3642446728ISBN 13: 9783642446726
Anbieter: Kennys Bookstore, Olney, MD, USA
Buch
Zustand: New. Combating Fungal Infections explores fungal diseases in humans and animals, focusing on the management, fungal pathogens and recent advances in treatment. Issues of antifungal drug toxicity are also discussed, in addition to treatment resistance and diagnostic approaches to fungal infections. Editor(s): Ahmad, Iqbal; Owais, Mohammad; Shahid, Mohammed; Aqil, Farrukh. Num Pages: 559 pages, biography. BIC Classification: MJCM; MMFM; MMG; PSG. Category: (G) General (US: Trade). Dimension: 235 x 155 x 29. Weight in Grams: 848. . 2014. Paperback. . . . . Books ship from the US and Ireland.
Verlag: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG, 2010
ISBN 10: 3642121721ISBN 13: 9783642121722
Anbieter: Kennys Bookstore, Olney, MD, USA
Buch
Zustand: New. Combating Fungal Infections explores fungal diseases in humans and animals, focusing on the management, fungal pathogens and recent advances in treatment. Issues of antifungal drug toxicity are also discussed, in addition to treatment resistance and diagnostic approaches to fungal infections. Editor(s): Ahmad, Iqbal; Owais, Mohammad; Shahid, Mohammed; Aqil, Farrukh. Num Pages: 539 pages, biography. BIC Classification: MJCM; MMFM; MMG; PSG. Category: (P) Professional & Vocational. Dimension: 243 x 164 x 43. Weight in Grams: 1078. . 2010. 2010th Edition. hardcover. . . . . Books ship from the US and Ireland.